Cytopenias and Infectious Complications Following CD19-Directed CAR-T cell Therapy in Patients with B-ALL

Key Points

• Cytopenias commonly occur, leading to increased risk of severe infections.
• Overall, 30% of patients developed significant infections during treatment.
• Analysis of clinical outcomes focused on patients with B-ALL receiving CAR-T therapy.
• These findings underscore the importance of monitoring patients for infections post-therapy.